Almost all doses of Mounjaro, Zepbound in short supply through Q2
The FDA updated its drug shortages list this week, noting that most of its injections of diabetes drug Mounjaro and weight loss drug Zepbound will be in short supply through the second quarter.
All but one dose of each drug — 2.5 mg of Mounjaro and 2.5 mg of Zepbound — are listed as experiencing “limited availability,” according to the FDA.
Zepbound was approved for weight loss in November and already pulled in $175.8 million as of February. The company also announced Wednesday that it would file for a label expansion for the drug in sleep apnea this year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.